Pharmacokinetic Modelling of a Parent Drug and its Metabolite: Atracurium and Laudanosine

Vladimir Nigrovic, Mounir F Banoub

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A pharmacokinetic model was designed to describe simultaneously the plasma concentrations of atracurium and its metabolite laudanosine. The proposed model satisfactorily fits the observations and is based on the assumptions that the parent drug spontaneously degrades to laudanosine at the rate comparable with that observed in vitro at pH 7.4 and 37°C; that 2 molecules of laudanosine are formed from 1 molecule of atracurium; that an initial very rapid decay of a fraction of the atracurium dose is responsible for the initially high plasma laudanosine concentrations; that the rapid disappearance of atracurium from plasma is accounted for by its spontaneous degradation and by the sequestration of atracurium in a deep compartment; and that laudanosine formed from atracurium is added to its central compartment, with its disposition described by a simple 2-compartment model with elimination from the central compartment. The model projects that about 43% of the atracurium dose is rapidly converted to laudanosine and that nearly the whole injected amount of atracurium is degraded to laudanosine.

Original languageEnglish (US)
Pages (from-to)396-408
Number of pages13
JournalClinical Pharmacokinetics
Volume22
Issue number5
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Atracurium
Pharmacokinetics
Pharmaceutical Preparations
laudanosine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetic Modelling of a Parent Drug and its Metabolite : Atracurium and Laudanosine. / Nigrovic, Vladimir; Banoub, Mounir F.

In: Clinical Pharmacokinetics, Vol. 22, No. 5, 01.01.1992, p. 396-408.

Research output: Contribution to journalArticle

Nigrovic, Vladimir ; Banoub, Mounir F. / Pharmacokinetic Modelling of a Parent Drug and its Metabolite : Atracurium and Laudanosine. In: Clinical Pharmacokinetics. 1992 ; Vol. 22, No. 5. pp. 396-408.
@article{3c5cc8568bb94bd88daaf0aca38bbcd5,
title = "Pharmacokinetic Modelling of a Parent Drug and its Metabolite: Atracurium and Laudanosine",
abstract = "A pharmacokinetic model was designed to describe simultaneously the plasma concentrations of atracurium and its metabolite laudanosine. The proposed model satisfactorily fits the observations and is based on the assumptions that the parent drug spontaneously degrades to laudanosine at the rate comparable with that observed in vitro at pH 7.4 and 37°C; that 2 molecules of laudanosine are formed from 1 molecule of atracurium; that an initial very rapid decay of a fraction of the atracurium dose is responsible for the initially high plasma laudanosine concentrations; that the rapid disappearance of atracurium from plasma is accounted for by its spontaneous degradation and by the sequestration of atracurium in a deep compartment; and that laudanosine formed from atracurium is added to its central compartment, with its disposition described by a simple 2-compartment model with elimination from the central compartment. The model projects that about 43{\%} of the atracurium dose is rapidly converted to laudanosine and that nearly the whole injected amount of atracurium is degraded to laudanosine.",
author = "Vladimir Nigrovic and Banoub, {Mounir F}",
year = "1992",
month = "1",
day = "1",
doi = "10.2165/00003088-199222050-00006",
language = "English (US)",
volume = "22",
pages = "396--408",
journal = "Clinical Pharmacokinetics",
issn = "0312-5963",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetic Modelling of a Parent Drug and its Metabolite

T2 - Atracurium and Laudanosine

AU - Nigrovic, Vladimir

AU - Banoub, Mounir F

PY - 1992/1/1

Y1 - 1992/1/1

N2 - A pharmacokinetic model was designed to describe simultaneously the plasma concentrations of atracurium and its metabolite laudanosine. The proposed model satisfactorily fits the observations and is based on the assumptions that the parent drug spontaneously degrades to laudanosine at the rate comparable with that observed in vitro at pH 7.4 and 37°C; that 2 molecules of laudanosine are formed from 1 molecule of atracurium; that an initial very rapid decay of a fraction of the atracurium dose is responsible for the initially high plasma laudanosine concentrations; that the rapid disappearance of atracurium from plasma is accounted for by its spontaneous degradation and by the sequestration of atracurium in a deep compartment; and that laudanosine formed from atracurium is added to its central compartment, with its disposition described by a simple 2-compartment model with elimination from the central compartment. The model projects that about 43% of the atracurium dose is rapidly converted to laudanosine and that nearly the whole injected amount of atracurium is degraded to laudanosine.

AB - A pharmacokinetic model was designed to describe simultaneously the plasma concentrations of atracurium and its metabolite laudanosine. The proposed model satisfactorily fits the observations and is based on the assumptions that the parent drug spontaneously degrades to laudanosine at the rate comparable with that observed in vitro at pH 7.4 and 37°C; that 2 molecules of laudanosine are formed from 1 molecule of atracurium; that an initial very rapid decay of a fraction of the atracurium dose is responsible for the initially high plasma laudanosine concentrations; that the rapid disappearance of atracurium from plasma is accounted for by its spontaneous degradation and by the sequestration of atracurium in a deep compartment; and that laudanosine formed from atracurium is added to its central compartment, with its disposition described by a simple 2-compartment model with elimination from the central compartment. The model projects that about 43% of the atracurium dose is rapidly converted to laudanosine and that nearly the whole injected amount of atracurium is degraded to laudanosine.

UR - http://www.scopus.com/inward/record.url?scp=0026515132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026515132&partnerID=8YFLogxK

U2 - 10.2165/00003088-199222050-00006

DO - 10.2165/00003088-199222050-00006

M3 - Article

C2 - 1505145

AN - SCOPUS:0026515132

VL - 22

SP - 396

EP - 408

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

SN - 0312-5963

IS - 5

ER -